The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Modified docetaxel and cisplatin in combination with capecitabine (DCX) as first-line treatment in HER2-negative advanced gastric cancer.
Ahmet Bilici
No relevant relationships to disclose
Fatih Selcukbiricik
No relevant relationships to disclose
Nazan Demir
No relevant relationships to disclose
Bala Basak Oven Ustaalioglu
No relevant relationships to disclose
Mustafa Dikilitas
No relevant relationships to disclose
Ozcan Yildiz
No relevant relationships to disclose